September 6, 2022 - Sucraid® (sacrosidase) Oral Solution

Day: September 6, 2022

QOL Medical, LLC Receives FDA Approval of Sucraid^® (sacrosidase) Oral Solution Single-Use Containers for Patients with Congenital Sucrase-Isomaltase Deficiency (CSID)

Vero Beach, Florida—(PR NEWSWIRE)—QOL Medical, LLC, a ground-breaking, rare disease pharmaceutical company, announced today that the United States (U.S.) Food & Drug Administration (FDA) approved Sucraid® single-use containers for patients more than 33 lb (15 kg) with Congenital Sucrase-Isomaltase Deficiency (CSID). Currently, Sucraid® (sacrosidase) Oral Solution is the only pharmaceutical treatment for CSID in children and adults. […]

Written by QOLAdmin on September 6, 2022

IMPORTANT SAFETY INFORMATION:

Important Safety Information for Sucraid^® (sacrosidase) Oral Solution

Tell your doctor if you are allergic to, have ever had a reaction to, or have ever had difficulty taking yeast, yeast products, papain, or glycerin (glycerol).
Sucraid^® may cause a serious allergic reaction. If you notice any swelling or have difficulty breathing, get emergency help right away.
Sucraid^® does not break down some sugars that come from the digestion of starch. You may need to restrict the amount of starch in your diet. Your doctor will tell you if you should restrict starch in your diet.
Tell your doctor if you have diabetes, as your blood glucose levels may change if you begin taking Sucraid^®. Your doctor will tell you if your diet or diabetes medicines need to be changed.
Some patients treated with Sucraid^® may have worse abdominal pain, vomiting, nausea, or diarrhea. Constipation, difficulty sleeping, headache, nervousness, and dehydration have also occurred in patients treated with Sucraid^®. Check with your doctor if you notice these or other side effects.
Sucraid^® has not been tested to see if it works in patients with secondary (acquired) sucrase deficiency.
NEVER HEAT SUCRAID^® OR PUT IT IN WARM OR HOT BEVERAGES OR INFANT FORMULA. Do not mix Sucraid^® with fruit juice or take it with fruit juice. Take Sucraid^® as prescribed by your doctor. Normally, half of the dose of Sucraid^® is taken just before a meal or snack and the other half is taken during the meal or snack.
Sucraid^® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid^®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Indication

Sucraid^® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Day: September 6, 2022

QOL Medical, LLC Receives FDA Approval of Sucraid® (sacrosidase) Oral Solution Single-Use Containers for Patients with Congenital Sucrase-Isomaltase Deficiency (CSID)

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

Indication

QOL Medical, LLC Receives FDA Approval of Sucraid^® (sacrosidase) Oral Solution Single-Use Containers for Patients with Congenital Sucrase-Isomaltase Deficiency (CSID)

Important Safety Information for Sucraid^® (sacrosidase) Oral Solution